Semaglutide na iya narkar da mai, kuma na iya rage ƙarfin tsoka. Wani babban gwaji na mataki na 2 da aka wallafa a The Lancet ya binciki ko dakile “birkin” jiki kan girman tsoka zai iya hana wannan ragin. Amsa ita ce eh, amma da wasu sharuɗɗa, kuma wani salo na maganin ya nuna alamun rashin lafiya da ya kamata a kula da su.
Ga abin da gwajin COURAGE ya gano, abin da ba ya gano, da abin da masu amfani da GLP‑1 za su iya yi a yau.
Matsalar: Ragin Kiba Ba Fat Ba Kawai
Ragin kiba da magungunan GLP‑1 receptor agonists ke haifarwa yana zuwa da raguwar tsoka sosai. A cikin COURAGE, waɗanda suka karɓi semaglutide da placebo sun rasa 6.6 % na lean mass a makonni 26 (95 % CI −7.4 zuwa −5.7). A ɓangaren makonni 52, ƙungiyar placebo ta rasa 7.3 % na lean mass.
Lean mass ba daidai yake da tsokar ƙashi ba, amma shi ne ma’aunin farko da aka yi amfani da shi a gwajin kuma ana ɗaukarsa wakilin yanayin ƙoshin lafiya.
Shawara: Dakile Myostatin (GDF8) da Activin A
GDF8, wanda aka fi sani da myostatin, da activin A suna aiki ta hanyar masu karɓar ActRIIA/B a matsayin masu hana ci gaban tsoka. Regeneron ta haɓaka nau’ikan antibodies guda biyu:
- Trevogrumab, wanda ke dakile GDF8; ana ba da shi a kowane mako ta allurar subcutaneous.
- Garetosmab, wanda ke dakile activin A; ana ba da shi a cikin infusion na jini duk bayan makonni 4.
Gwaji: Mutane 975, Bangarori Biyu
Binciken ya kasance double‑blind, placebo‑controlled, mataki na 2 a cibiyoyi 60 a Amurka. An haɗa mutane 975 masu kiba (BMI ≥ 30), shekaru matsakaicin 49, da BMI matsakaicin 36.7. Kashi sittin da huɗu cikin ɗari (64 %) mata ne. Kowa ya sha semaglutide, an daidaita zuwa 2.4 mg a kowane mako.
- Bangare A (makonni 26, n=605): placebo, trevogrumab 200 mg, trevogrumab 400 mg, ko trevogrumab 400 mg da garetosmab 10 mg/kg.
- Bangare B (makonni 52, n=376): placebo, trevogrumab 25 mg, ko trevogrumab 75 mg.
Lambobin Manyan Sakamako: Lean Mass
Kididdigar da ke ƙasa suna nuna bambancin magani da aka kiyasta idan aka kwatanta da semaglutide da placebo.
Bangare A (makonni 26):
- Trevogrumab 200 mg: +3.1 % (95 % CI 1.9 zuwa 4.3)
- Trevogrumab 400 mg: +2.7 % (1.5 zuwa 4.0)
- Trevogrumab 400 mg da garetosmab: +4.5 % (3.1 zuwa 5.9)
Bangare B (makonni 52):
- Trevogrumab 25 mg: +1.5 % (‑0.3 zuwa 3.3), ba a samu muhimmanci na ƙididdiga ba
- Trevogrumab 75 mg: +3.1 % (1.3 zuwa 4.9)
Magungunan sun rage raguwar lean mass amma ba su kawar da ita gaba ɗaya ba. Takaitaccen bayanin ba ya ba da cikakken canjin lean mass na rukuni‑rukuni, don haka duk wani “ragi na ƙarshe” da muka ƙirga, yana kanmu ne.
Rage Mai Da Kiba: Abin Mamaki
Ana ɗaukar magungunan da ke tsare tsoka a matsayin na da ƙyamar rage mai. A wannan binciken, a wasu rukuni, aka samu akasin haka.
- Rukuni na placebo ya rasa 15.6 % na maɗan mai a Bangare A.
- Trevogrumab 400 mg kadai ya haifar da raguwar mai mai girma (ETD ‑3.4 %).
- Haɗin trevogrumab da garetosmab ya ƙara raguwar mai sosai (ETD ‑11.7 %).
- Nauyin jiki ya sauka 10.6 % a kan semaglutide da placebo; haɗin ya ƙara inganta wannan da ƙarin 2.7 %.
- Babu wani rukuni a Bangare A ko B da ya nuna bambanci mai mahimmanci a kan maɗan mai ko nauyin jiki.
Kalubalen: Tsarin Tsaron Haɗin
Trevogrumab kadai, a kowane ƙima (25, 75, 200 ko 400 mg), an samu karɓuwa mai kyau, tare da tsarin tsaro da ya yi kama da semaglutide da placebo. Matsalolin hanji sune mafi yawan faruwa kuma sun zo a kusan adadi iri ɗaya a dukkan rukuni. Mafi yawan mummunan abubuwa sun kasance masu sauƙi zuwa matsakaici.
Rukuni na trevogrumab 400 mg da garetosmab ya bambanta:
- Mummunan abubuwa masu tsanani: 14 daga 149 (9 %)
- Dakatar da magani: 48 daga 149 (32 %)
- Ciwon tsoka (muscle spasms): 61 daga 149 (41 %), idan aka kwatanta da 8 % (23 daga 299) a rukuni na trevogrumab kadai da 5 % (7 daga 151) a placebo
- Mutuwar mutane: biyu a lokacin gwajin, duka a wannan rukuni. Masu binciken ba su gano alaƙa kai tsaye ba.
Mawallafa sun ƙare da cewa haɗin ba shi da “favourable safety and tolerability.” Sun gabatar da trevogrumab kadai a matsayin hujja mafi inganci.
Gargadi
- Tallafin kuɗi: Regeneron ta ɗauki nauyin gwajin, kuma yawancin marubuta ma’aikatan Regeneron ne da masu hannun jari.
- Mataki na 2: Manyan manufofi su ne yanayin jiki da nauyi, ba aikin jiki ba. Mawallafa suna cewa akwai buƙatar ƙarin bincike don tantance ko kiyaye lean mass zai haifar da ingantaccen aiki da lafiya ta metabolic.
- Ba a amince da su ba: Babu ɗayan antibodies da aka amince da su don wannan amfani. Ba za a iya samun su a matsayin kari ko takardar magani ba.
- Lokacin janye magani: Bangare A ya ƙunshi makonni 26 bayan an daina semaglutide, amma takaitaccen ba ya bayar da sakamako daga wannan ɓangaren.
Abin Da Wannan Ke Nufi Ga Masu Amfani Da GLP‑1 Yanzu
Wannan jagora ne na gabaɗaya, ba sakamakon binciken da ya gwada motsa jiki ko abinci ba.
- Kada ku bi wannan nau’in magani. Babu ƙuduri, lokaci ko “wanda ya dace da shi” domin babu wani abu da ake samu a wajen gwaje‑gwaje.
- Mayar da hankali kan furotin da horon ƙarfi. Waɗannan su ne hanyoyin da aka fi ba da shawara, masu sauƙi, don kare tsoka yayin ragin kiba. Ku tattauna adadin furotin da shirin motsa jiki da likita ko ƙwararren mai ba da abinci, musamman idan kuna da cutar koda.
- Ku bi diddigin fiye da sikeli. Ƙarfi, aiki da, inda zai yiwu, yanayin jiki na ba ku ƙarin bayani fiye da nauyi kai‑kai.
Jadawalin Lokaci
Takaitaccen bai ba da lokacin amincewa ba. COURAGE yana ci gaba amma ba a karɓar sababbin mahalarta ba. Saboda tsarin tsaron haɗin ya kasance mai damuwa kuma ba a tantance aikin jiki ba, za a buƙaci ƙarin gwaje‑gwaje kafin kowanne hukuma ta yi la’akari da waɗannan magungunan. Ku ɗauki wannan a matsayin alamar farko mai ɗaukar hankali, ba zaɓi da ke tafe nan ba.